Nu Skin Enterprises, Inc. reports developments tied to its beauty and wellness business, affiliate opportunity platform and international market operations. Company updates commonly cover quarterly revenue and earnings, customer, paid affiliate and sales leader trends, dividend declarations, cost discipline and product commercialization across Nu Skin personal care, Pharmanex nutrition and ageLOC anti-aging brands.
Recurring news also includes the rollout of Prysm iO, an intelligent wellness platform that uses skin scans to provide antioxidant-related insights, and activity at Rhyz, the company’s strategic investment arm for consumer, technology and manufacturing businesses in beauty, wellness and lifestyle categories. Leadership appointments and operating-structure changes are also part of the company’s public updates.
Nu Skin (NYSE: NUS) reported Q1 2026 revenue of $320.6 million (down 12% year-over-year; +1.1% FX or $3.9 million). GAAP EPS was $0.04 ($0.14 excluding certain charges). Customers totaled 669,535 (down 14%); paid affiliates 120,850 (down 8%).
Management highlighted Prysm iO™ rollout ahead of a full consumer launch in H2 2026 and an anticipated formal launch in India in late 2026. Q2 revenue guidance is $330–360M; 2026 revenue guide is $1.35–1.50B. The company returned $8M to shareholders via dividends and buybacks and refinanced debt to extend liquidity.
Nu Skin Enterprises (NYSE: NUS) declared a quarterly cash dividend of $0.06 per share. The dividend will be paid on June 10, 2026 to shareholders of record as of May 29, 2026. This action reflects the board's approved cash distribution to shareholders.
Nu Skin (NYSE: NUS) will release first quarter 2026 results after market close on Thursday, May 7, 2026. Management will host a conference call the same day at 5:00 p.m. ET to discuss results and upcoming business initiatives.
The live webcast and financial materials will be available at ir.nuskin.com, with a replay accessible through Thursday, May 21, 2026.
Nu Skin (NYSE: NUS) launched Prysm iO, an AI-powered, fingertip skin scanner that measures carotenoid antioxidant levels in 15 seconds and is available in the U.S. for $375. The device uses patent-pending Spectral Rai Technology and a database of >20 million scans.
Clinical validation (97 participants) showed strong correlation with blood serum (R² = 0.75–0.77); Prysm iO provides a Nutrition Health Score and integrates with Nu Skin supplements.
Nu Skin Enterprises (NYSE: NUS) appointed Chelsea Lantz as interim Chief Financial Officer, effective March 20, 2026, after James Thomas stepped down to pursue an outside opportunity. The board has started a formal search for a permanent CFO while Lantz will continue cost-improvement and operational performance efforts.
Lantz joined Nu Skin in 2011, served as corporate controller since 2023, and led initiatives that the company says produced a significant year-over-year increase in EPS. She previously worked at PricewaterhouseCoopers and holds a Master of Accounting from Utah State University.
Nu Skin (NYSE:NUS) appointed Chayce Clark as chief operating officer, effective March 9, 2026, while he retains his chief legal officer role.
Clark will lead revenue performance and end-to-end operations, overseeing global sales, product innovation, technology platforms, brand programs and legal services across nearly 50 markets, and will support the Prysm iO rollout and India expansion.
Nu Skin (NYSE: NUS) reported Q4 2025 revenue of $370.3M (down 16.9%) and full-year 2025 revenue of $1.49B (down 14.3%). Fiscal 2025 EPS was $3.18 with more than 50% earnings growth year-over-year. Q4 gross margin improved to 70.7% and operating margin was 6.3%.
The company provided Q1 2026 revenue guidance of $320–$340M and full-year 2026 revenue guidance of $1.35–$1.50B with EPS of $0.80–$1.20. Management highlighted Prysm iO device rollout and India pre-market work as growth initiatives.
Nu Skin Enterprises (NYSE: NUS) declared a quarterly cash dividend of $0.06 per share. The dividend is payable on Mar. 11, 2026 to shareholders of record on Feb. 27, 2026.
This notice communicates the declared per-share amount, record date, and payment date for investors.
Nu Skin (NYSE: NUS) announced the relaunch of Dr. Joseph Chang’s bestselling book The Aging Myth with 15 years of additional research on measurable biology and cellular wellness.
The updated edition links expanded chapters on cellular resilience, oxidative stress, and measurable biomarkers to Nu Skin’s Prysm iO platform and ageLOC technologies. The digital edition is available today for $9.99 on major retailers.
Stonegate Capital Partners attended the ICR 2026 conference in Dallas on January 14, 2026, where it moderated a fireside chat with Nu Skin (NASDAQ: NUS). Stonegate also attended presentations from LifeVantage (LFVN), USANA (USNA), Beachbody (BODI) and Strauss Group (STRS), and observed an RSM panel on "cutting through the AI hype." The release notes common themes across retail, hybrid and DTC go-to-market models in nutrition, beauty and wellness sectors and points readers to the full announcement for images and bios.